News
Morgan Stanley analyst Michael Ulz maintained a Buy rating on Silence Therapeutics (SLN – Research Report) today and set a price target of $49.00. The company’s shares closed last Friday at ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Silence Therapeutics (SLN – Research Report) and Warby Parker (WRBY – Research Report) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback